Match the following columns and select the correct option. [2020]
| Column-I | Column-II |
|---|---|
| (A) Bt cotton | (i) Gene therapy |
| (B) Adenosine deaminase deficiency | (ii) Cellular defence |
| (C) RNAi | (iii) Detection of HIV infection |
| (D) PCR | (iv) Bacillus thuringiensis |
(A) → (iv), (B) → (i), (C) → (ii), (D) → (iii)
(A) → (iii), (B) → (ii), (C) → (i), (D) → (iv)
(A) → (ii), (B) → (iii), (C) → (iv), (D) → (i)
(A) → (i), (B) → (ii), (C) → (iii), (D) → (iv)
Which of the following statements is not correct? [2020]
In man insulin is synthesised as a proinsulin.
The proinsulin has an extra peptide called C-peptide.
The functional insulin has A and B chains linked together by hydrogen bonds.
Genetically engineered insulin is produced in E. coli.
(3)
Insulin consists of two short polypeptide chains: Chain A and Chain B, that are linked together by disulphide bridges.
Which kind of therapy was given in 1990 to a four-year-old girl with adenosine deaminase (ADA) deficiency? [2016]
Gene therapy
Chemotherapy
Immunotherapy
Radiation therapy
(1)
Gene therapy is a technique of genetic engineering which involves replacement of a faulty/disease causing gene by a normal healthy functional gene. The first clinical gene therapy was given in 1990 to a 4-year old girl with adenosine deaminase (ADA) deficiency. This enzyme is very important for the immune system to function. The deficiency of this enzyme can lead to severe combined immune deficiency (SCID).
The two polypeptides of human insulin are linked together by [2016]
covalent bond
disulphide bridges
hydrogen bonds
phosphodiester bond
(2)
Human insulin is made up of 51 amino acids arranged in two polypeptide chains. Chain A has 21 amino acids and chain B has 30 amino acids. The two polypeptide chains are interconnected by disulphide bridges or S-S-linkages.
The first human hormone produced by recombinant DNA technology is [2014]
insulin
estrogen
thyroxin
progesterone
(1)
The recombinant DNA technological processes have made great impact in the area of health care by mass production of safe and more effective therapeutic drugs. In 1983, Eli Lily, an American company, first prepared two DNA sequences corresponding to A and B chains of human insulin and introduced them in plasmids of Escherichia coli to produce insulin chains. Chains A and B were produced separately, extracted and combined by creating disulphide bonds to form human insulin (humulin).
